← Eichor
Study identifier: NCT06055738 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC

Condition: Locally Advanced Cervical Cancer  ·  Sponsor: Tang-Du Hospital

PhasePhase 2
Planned participants20
Who can joinFemale, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a prospective, single arm, phase II clinical study to evaluate the efficacy and safety of Zimberelimab combined with albumin-bound paclitaxel and cisplatin as neoadjuvant therapy for locally advanced cervical cancer.

This description comes directly from the study's public registry record.

Talk to the study team

Hongxi Zhao, PhD  ·  +8615094088350  ·  zhaohx@fmmu.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Hongxi ZhaoXi'an, Shaanxi, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06055738